PAQR3 modulates blood cholesterol level by facilitating interaction between LDLR and PCSK9

Low-density lipoprotein cholesterol (LDL-C) is the hallmark of atherosclerotic cardiovascular diseases. The hepatic LDL receptor (LDLR) plays an important role in clearance of circulating LDL-C. PCSK9 facilitates degradation of LDLR in the lysosome and antagonizing PCSK9 has been successfully used in the clinic to reduce blood LDL-C level. Here we identify a new player that modulates LDLR interaction with PCSK9, thus controlling LDLR degradation and cholesterol homeostasis.

Source: Metabolism - Clinical and Experimental - February 28, 2019 Category: Biomedical Science Authors: Meiqin Huang, Zilong Zhao, Qianqian Cao, Xue You, Siying Wei, Jingyu Zhao, Meijuan Bai, Yan Chen Source Type: research